Table 3 In vitro antifungal susceptibility testing of 201 clinical isolates into 5 antifungal agents
Species (No of isolates) | Antifungal agent | Resistant n(%)e | |||
|---|---|---|---|---|---|
Children (35) | Adults(166) | total | Pc | ||
Candida albicans(81) | Amphotericin B | 0 | 0 | 0b | – |
Flucytosine | 0 | 1(1.5) | 1(1.2)b | 0.618 | |
Fluconazole | 2(12.5) | 17(26.2) | 19(23.5) | 0.248 | |
Itraconazole | 8(50.0) | 22(33.8) | 30(37.0)b | 0.231 | |
Voriconazole | 4(25.0) | 20(30.8) | 24(29.6)b | 0.651 | |
Candida glabrata(73) | Amphotericin B | 1(5.6) | 0 | 1(1.4)b | 0.078 |
Flucytosine | 0 | 0 | 0b | – | |
Fluconazole | 1(5.6) | 5(9.1) | 6(8.2) | 0.635 | |
Itraconazole | 2(11.1) | 5(9.1) | 7(9.6)b | 0.801 | |
Voriconazole | 1(5.6) | 2(3.6) | 3(4.1)b | 0.722 | |
C.tropicalis(28) | Amphotericin B | 0 | 1(3.6) | 1(3.6)b | – |
Flucytosine | 0 | 1(3.6) | 1(3.6)b | – | |
Fluconazole | 0 | 11(39.3) | 11(39.3)b | – | |
Itraconazole | 0 | 11(39.3) | 11(39.3)b | – | |
Voriconazole | 0 | 12(42.9) | 12(42.9)b | – | |
C. krusei(6) | Amphotericin B | 0 | 0 | 0 | – |
Flucytosine | 0 | 0 | 0 | – | |
Fluconazolea | – | – | – | – | |
Itraconazole | 0 | 1(16.7) | 1(16.7)b | – | |
Voriconazole | 0 | 1(16.7) | 1(16.7)b | – | |
All of isolates (201) | Amphotericin B | 1(2.9) | 1(0.6) | 2(1.0) | 0.222 |
Flucytosine | 0(0) | 2(1.2) | 2(1..0) | 0.513 | |
Fluconazolea | 3(8.6) | 33(20.6) | 36(18.5) | 0.096 | |
Itraconazole | 10(28.6) | 40(24.1) | 50(24.9) | 0.578 | |
Voriconazole | 5(14.3) | 34(20.5) | 39(19.4) | 0.400 | |